Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo

Journal of Immunology

Volumn 177, Issue 3, 2006, Pages 1679-1688

  Li, Yonghai ^a   Chu, Niansheng ^a   Rostami, Abdolmohamad ^a   Zhang, Guang Xian ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 23 P19; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; BONE MARROW CELL; CELL POLARITY; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH2 CELL; TREATMENT OUTCOME;

EID: 33746190828     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.3.1679     Document Type: Article

References (53)

1. Blom, B., and H. Spits. 2006. Development of human lymphoid cells. Annu. Rev. Immunol. 24: 287-284.
2. + T cell responses: the alternative approaches. Annu. Rev. Immunol. 15: 297-322.
3. Parham, C., M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol 168: 5699-5708.
4. Lugo-Villarino, G., R. Maldonado-Lopez, R. Possemato, C. Penaranda, and L. H. Glimcher. 2003. T-bet is required for optimal production of IFN-γ and antigen-specific T cell activation by dendritic cells. Proc. Natl. Acad. Sci. USA 100: 7749-7754.
5. Kadowaki, N., S. Ho, S. Antonenko, R. W. Malefyt, R. A. Kastelein, F. Bazan, and Y. J. Liu. 2001. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194: 863-869.
6. Belladonna, M. L., J. C. Renauld, R. Bianchi, C. Vacca, F. Fallarino, C. Orabona, M. C. Fioretti, U. Grohmann, and P. Puccetti. 2002. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168: 5448-5454.
7. Frucht, D. M., T. Fukao, C. Bogdan, H. Schindler, J. J. O'Shea, and S. Koyasu. 2001. IFN-γ production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 22: 556-560.
8. Pulendran, B., J. Lingappa, M. K. Kennedy, J. Smith, M. Teepe, A. Rudensky, C. R. Maliszewski, and E. Maraskovsky. 1997. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. 159: 2222-2231.
9. Kalinski, P., and M. Moser. 2005. Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. 5: 251-260.
10. Kapsenberg, M. L., and P. Kalinski. 1999. The concept of type 1 and type 2 antigen-presenting cells. Immunol. Lett. 69: 5-6.
11. Tas, S. W., E. C. de Jong, N. Hajji, M. J. May, S. Ghosh, M. J. Vervoordeldonk, and P. P. Tak. 2005. Selective inhibition of NF-κB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. Eur. J. Immunol. 35: 1164-1174.
12. Zhang, G. X., S. Yu, B. Gran, J. Li, I. Siglienti, X. Chen, D. Calida, E. Ventura, M. Kamoun, and A. Rostami. 2003. Role of IL-12Rβ1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis. J. Immunol. 171: 4485-4492.
13. Yamamoto, K., M. Yamaguchi, N. Miyasaka, and O. Miura. 2003. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12R β2 subunit. Biochem. Biophys. Res. Commun. 310: 1188-1193.
14. Lang, R., A. L. Pauleau, E. Parganas, Y. Takahashi, J. Mages, J. N. Ihle, R. Rutschman, and P. J. Murray. 2003. SOCS3 regulates the plasticity of gp130 signaling. Natl. Immunol. 4: 546-544.
15. Seki, Y., H. Inoue, N. Nagata, K. Hayashi, S. Fukuyama, K. Matsumoto, O. Komine, S. Hamano, K. Himeno, K. Inagaki-Ohara, et al. 2003. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Natl. Med. 9: 1047-1054.
16. Stoiber, D., P. Kovarik, S. Cohney, J. A. Johnston, P. Steinlein, and T. Decker. 1999. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-γ. J. Immunol. 163: 2640-2647.
17. Dalpke, A. H., S. Opper, S. Zimmermann, and K. Heeg. 2001. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J. Immunol. 166: 7082-7089.
18. Berlato, C., M. A. Cassatella, I. Kinjyo, L. Gatto, A. Yoshimura, and F. Bazzoni. 2002. Involvement of SOCS-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J. Immunol. 168: 6404-6411.
19. Jo, D., D. Liu, S. Yao, R. D. Collins, and J. Hawiger. 2005. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat. Med. 11: 892-898.
20. Jackson, S. H., C. R. Yu, R. M. Mahdi, S. Ebong, and C. E. Egwuagu. 2004. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J. Immunol. 172: 2307-2315.
21. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189: 587-592.
22. Zhang, G. X., S. Yu, Y. Li, E. S. Ventura, B. Gran, and A. Rostami. 2005. A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J. Neuroimmunol: 161: 101-112.
23. Benson, J. M., K. A. Campbell, Z. Guan, I. E. Gienapp, S. S. Stuckman, T. Forsthuber, and C. C. Whitacre. 2000. T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen. J. Clin. Invest. 106: 1031-1038.
24. Starr, R., T. A. Willson, E. M. Viney, L. J. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, and D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signaling. Nature 387: 917-914.
25. Takatori, H., H. Nakajima, S. Kagami, K. Hirose, A. Suto, K. Suzuki, M. Kubo, A. Yoshimura, Y. Saito, and I. Iwamoto. 2005. Stat5a inhibits IL-12-induced Th1 cell differentiation through the induction of suppressor of cytokine signaling 3 expression. J. Immunol. 174: 4105-4112.
26. Greenhalgh, C. J., and D. J. Hilton. 2001. Negative regulation of cytokine signaling. J. Leukocyte Biol. 70: 348-344.
27. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
28. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16: 495-521.
29. Gran, B., G. X. Zhang, and A. Rostami. 2004. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev. Immunol. 24: 111-128.
30. Bastos, K. R., J. M. Alvarez, C. R. Marinho, L. V. Rizzo, and M. R. Lima. 2002. Macrophages from IL-12 p40-deficient mice have a bias toward the M2 activation profile. J. Leukocyte Biol. 71: 271-278.
31. Bastos, K. R., de Deus Vieirade Moraes, C. A. Zago, C. R. Marinho, M. Russo, J. M. Alvarez, and M. R. D'Imperio Lima. 2005. Analysis of the activation profile of dendritic cells derived from the bone marrow of interleukin-12/ interleukin-23-deficient mice. Immunology 114: 499-506.
32. Banchereau, J., and A. K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5: 296-306.
33. Yadav, A., A. Kalita, S. Dhillon, and K. Banerjee. 2005. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J. Biol. Chem. 280: 31830-31840.
34. Grohmann, U., M. L. Belladonna, R. Bianchi, C. Orabona, E. Ayroldi, M. C. Fioretti, and P. Puccetti. 1998. IL-12 acts directly on DC to promote nuclear localization of NF-κB and primes DC for IL-12 production. Immunity 9: 315-323.
35. Grohmann, U., M. L. Belladonna, C. Vacca, R. Bianchi, F. Fallarino, C. Orabona, M. C. Fioretti, and P. Puccetti. 2001. Positive regulatory role of IL-12 in macrophages and modulation by IFN-γ. J. Immunol. 167: 221-227.
36. Segal, B. M., B. K. Dwyer, and E. M. Shevach. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187: 537-546.
37. Chang, H. C., S. Zhang, and M. H. Kaplan. 2002. Neonatal tolerance in the absence of Stat4- and Stat6-dependent Th cell differentiation. J. Immunol. 169: 4124-4128.
38. Xia, C. Q., and K. J. Kao. 2003. Suppression of interleukin-12 production through endogenously secreted interleukin-10 in activated dendritic cells: involvement of activation of extracellular signal-regulated protein kinase. Scand. J. Immunol. 58: 23-32.
39. Demangel, C., P. Bertolino, and W. J. Britton. 2002. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur. J. Immunol. 32: 994-1002.
40. De, S. T., M. M. Van, B. G. De, J. Urbain, O. Leo, and M. Moser. 1997. Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 27: 1229-1235.
41. Corinti, S., C. Albanesi, A. la Sala, S. Pastore, and G. Girolomoni. 2001. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166: 4312-4318.
42. Donnelly, R. P., H. Dickensheets, and D. S. Finbloom. 1999. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J. Interferon Cytokine Res. 19: 563-573.
43. Zhu, J., J. Cote-Sierra, L. Guo, and W. E. Paul. 2003. Stat5 activation plays a critical role in Th2 differentiation. Immunity 19: 739-734.
44. Egwuagu, C. E., C. R. Yu, M. Zhang, R. M. Mahdi, S. J. Kim, and I. Gery. 2002. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J. Immunol. 168: 3181-3187.
45. Uzel, G., D. M. Frucht, T. A. Fleisher, and S. M. Holland. 2001. Detection of intracellular phosphorylated STAT-4 by flow cytometry. Clin. Immunol. 100: 270-276.
46. de Jong, E. C., H. H. Smits, and M. L. Kapsenberg. 2005. Dendritic cell-mediated T cell polarization. Springer Semin. Immunopathol. 26: 289-307.
47. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914.
48. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
49. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
50. Kim S. H., S. Kim, C. H. Evans, S. C. Ghivizzani, T. Oligino, and P. D. Robbins. 2001. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J. Immunol. 166: 3499-3505.
51. Tarner, I. H., A. J. Slavin, J. McBride, A. Levicnik, R. Smith, G. P. Nolan, C. H. Contag, and C. G. Fathman. 2003. Treatment of autoimmune disease by adoptive cellular gene therapy. Ann. NY Acad. Sci. 998: 512-519.
52. Leach, M. W., E. A. Snyder, D. P. Sinha, and I. Y. Rosenblum. 1997. Safety evaluation of recombinant human interleukin-4. I. Preclinical studies. Clin. Immunol. Immunopathol. 83: 8-11.
53. Leach, M. W., M. E. Rybak, and I. Y. Rosenblum. 1997. Safety evaluation of recombinant human interleukin-4. II. Clinical studies. Clin. Immunol. Immunopathol. 83: 12-14.